Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Excited by strong phase II data, Novartis is exercising its option to ... that of patients on the highest dose of TQJ230 of 20 mg once-weekly, 98% saw Lp(a) levels drop below the recommended ...

A study published in Cell Metabolism looks at the artificial sweetener aspartame, insulin levels and blood inflammation in mice. Prof Naveed Sattar, Professor of Cardiometabolic Medicine/Honorary ...

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...

with doses above 75 mg given every 12 weeks, cutting levels by 95% or more after six months. Amgen still needs to show that the reduction in Lp(a) is accompanied by lower rates of cardiovascular ...

The data cutoff date for the current analysis of the study was August 8, 2024. With 29.1 months of median follow-up, 12% of ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The drug is currently approved in 12 mg doses. The high-dose applications ... The high-dose Spinraza is Biogen's answer to competitors such as Novartis' gene therapy Zolgensma.

On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) ...

Updated guidance on preventing atherosclerotic cardiovascular disease in people with dyslipidemia includes changes reflecting ...

Scalp psoriasis improvement was maintained with long-term tildrakizumab treatment in what researchers said is the first ...

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has ...